MedTrace Logo

Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer

NCT03114631 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-12-03

No results posted yet for this study

Summary

The trial evaluates the safety and efficacy of MUC-1/WT-1 peptide and/or tumor lysate-pulsed dendritic cell Immunotherapy for the patients with pancreatic cancer

Conditions

  • Dendritic Cells
  • Pancreatic Neoplasms

Interventions

BIOLOGICAL

Dendritic cells pulsed with tumor lysate

BIOLOGICAL

Dendritic cells pulsed with MUC-1/WT-1 peptides

Sponsors & Collaborators

  • Belarusian State Medical University

    collaborator OTHER

  • The Republican Research and Practical Center for Epidemiology and Microbiology

    lead OTHER

Principal Investigators

  • Alexander V. Prokharau, Prof. · Belarussian State Medical University, Minsk, Belarus

  • Andrei Y Hancharou, Dr. · The Republican Research and Practical Center for Epidemiology and Microbiology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-09
Primary Completion
2019-05-03
Completion
2019-05-23

Countries

  • Belarus

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03114631 on ClinicalTrials.gov